FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+26.79%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.4B
AUM Growth
+$12.4B
(+14%)
Cap. Flow
-$730M
Cap. Flow
% of AUM
-5.86%
Top 10 Holdings %
Top 10 Hldgs %
33.25%
Holding
138
New
31
Increased
25
Reduced
37
Closed
17
Top Buys
| 1 |
T-Mobile US
TMUS
|
$360M |
| 2 |
Aon
AON
|
$331M |
| 3 |
WUBA
58.COM INC
WUBA
|
$268M |
| 4 |
Bristol-Myers Squibb
BMY
|
$213M |
| 5 |
TIF
Tiffany & Co.
TIF
|
$186M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$1.65B |
| 2 |
Cigna
CI
|
$141M |
| 3 |
General Dynamics
GD
|
$139M |
| 4 |
Fidelity National Information Services
FIS
|
$138M |
| 5 |
Wabtec
WAB
|
$115M |
Sector Composition
| 1 | Healthcare | 42.69% |
| 2 | Communication Services | 18.47% |
| 3 | Technology | 10.46% |
| 4 | Financials | 7.55% |
| 5 | Industrials | 3.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TIF
26
DELISTED
Tiffany & Co.
TIF
| $186M | 1.49% | +1,527,698 | New | +$186M |
|
27
Iovance Biotherapeutics
IOVA
$807M
| $179M | 1.44% | 6,537,500 +787,500 | +14% | +$21.6M |
|
28
New York Times
NYT
$9.74B
| $174M | 1.39% | +4,137,542 | New | +$174M |
|
|
29
General Dynamics
GD
$87.3B
| $172M | 1.38% | 1,151,481 -932,200 | -45% | -$139M |
|
30
Ascendis Pharma
ASND
$11.8B
| $169M | 1.35% | 1,140,000 -236,349 | -17% | -$35M |
|
|
BMY.RT
31
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $158M | 1.27% | 44,200,000 +9,000,000 | +26% | +$32.2M |
|
32
Blackstone
BX
$134B
| $157M | 1.26% | 2,768,319 +2,365,508 | +587% | +$134M |
|
33
Alnylam Pharmaceuticals
ALNY
$58.5B
| $156M | 1.24% | 1,050,000 -450,000 | -30% | -$66.6M |
|
34
Qiagen
QGEN
$10.1B
| $123M | 0.99% | 2,881,000 -79,986 | -3% | -$3.42M |
|
|
WMGI
35
DELISTED
Wright Medical Group Inc
WMGI
| $122M | 0.98% | 4,100,000 +1,825,000 | +80% | +$54.2M |
|
36
Fate Therapeutics
FATE
$120M
| $120M | 0.96% | 3,500,000 +500,000 | +17% | +$17.2M |
|
|
PLYA
37
DELISTED
Playa Hotels & Resorts
PLYA
| $111M | 0.89% | 30,606,930 | – | – |
|
38
TransUnion
TRU
$17.2B
| $104M | 0.83% | 1,192,747 -831,140 | -41% | -$72.3M |
|
|
CZR
39
DELISTED
Caesars Entertainment Corporation
CZR
| $97.2M | 0.78% | +8,015,000 | New | +$97.2M |
|
|
40
Cigna
CI
$80.3B
| $93.8M | 0.75% | 500,000 -750,000 | -60% | -$141M |
|
41
Enanta Pharmaceuticals
ENTA
$180M
| $87.9M | 0.7% | 1,750,000 | – | – |
|
|
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $84.5M | 0.68% | 875,000 +445,000 | +103% | +$43M |
|
43
Sarepta Therapeutics
SRPT
$1.78B
| $84.2M | 0.67% | 525,000 +175,000 | +50% | +$28.1M |
|
44
New Oriental
EDU
$7.85B
| $82.2M | 0.66% | +631,000 | New | +$82.2M |
|
|
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $74.2M | 0.59% | 650,000 +50,000 | +8% | +$5.71M |
|
46
Apellis Pharmaceuticals
APLS
$3.48B
| $73.5M | 0.59% | 2,250,000 +250,000 | +13% | +$8.17M |
|
|
BRMK
47
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $67.9M | 0.54% | 7,170,213 | – | – |
|
48
Agios Pharmaceuticals
AGIO
$2.19B
| $66.9M | 0.54% | 1,250,000 | – | – |
|
49
FibroGen
FGEN
$47.8M
| $65.9M | 0.53% | 1,625,000 +25,333 | +2% | +$1.03M |
|
|
KRTX
50
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $64.1M | 0.51% | 575,000 +7,953 | +1% | +$886K |
|